Clinical Trials

  • REBIRTH - Study of Bromocriptine in Women with Peripartum Cardiomyopathy (PPCM)

    Principal Investigator:

    Jennifer Haden Haythe, MD
    We are doing this study to test the use of a drug called bromocriptine for women with a condition called Peripartum cardiomyopathy (PPCM). The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill.

  • REST: Sleep Study for High School Students

    Principal Investigator:

    Brooke Aggarwal, EdD, MS, FAHA
    High school students ages 14-18 and their parent(s) may be eligible to participate in a 12-week (consisting of a 6-week pre-pilot and 6-week pilot) sleep health education program.

  • REST: Sleep Study for High School Students

    Principal Investigator:

    Brooke Aggarwal, EdD, MS, FAHA
    High school students ages 14-18 and their parent(s) may be eligible to participate in a 12-week (consisting of a 6-week pre-pilot and 6-week pilot) sleep health education program.

  • Study of Dronedarone in Patients with Atrial Fibrillation (AF)

    Principal Investigator:

    Elaine Y Wan, MD
    Atrial fibrillation (AFib) is an arrhythmia (abnormal heart rhythm) that causes the heart's upper chambers (the atria) to beat very fast and irregularly. The purpose of this study is to determine if early study treatment with the medicine dronedarone is more effective than usual care alone for the prevention of unplanned cardiovascular hospitalization. A computer will randomly assign you (like the flip of a coin) to receive either the study intervention or usual care. Both you and your study doctors will know to which group you have been assigned. The study intervention is the oral (by mouth...

  • The ALL-RISE Study

    Principal Investigator:

    Margaret B. McEntegart, MD
    This is a prospective, randomized, multi-center, controlled post-market study. The ALL-RISE study is looking at Fractional flow reserve (FFR) which is a medical test that doctors use to check how narrow the heart arteries are and decide if a stent or other treatment is needed. It helps doctors determine if the blockage is causing significant reduction in blood flow and guides them in making better choices for how to treat patients. The goal is to see if an image-based software system called FFRangio can accurately measures blood pressure and flow through the arteries as compared to using a...

  • The BREAK II Study: Breaking up Prolonged Inactivity to Improve Cardiometabolic Health

    Principal Investigator:

    Keith Diaz, PhD
    U.S. Adults spend on average 11 to 12 hours a day in sedentary behavior. Daily sedentary behavior is strongly associated with risk of cardiovascular disease. The purpose of the BREAK II research study is to answer two questions: (1) How frequent should periods of prolonged sedentary time be interrupted? and (2) What is the appropriate duration or length of time of these breaks in sedentary time? If you are 18 years old or older and have no history of chronic diseases, and no physical disability preventing ability to walk and a non-smoker you may be eligible for this study. Participants will...

  • The CORCINCH-HF Study: Study of AccuCinch in Patients with Symptomatic Heart Failure with Reduced Ejection Frraction (HFrEF)

    Principal Investigator:

    Gabriel Tal Sayer, MD
    This is a prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Repair System in patients with heart failure and reduced ejection fraction (HFrEF).

  • The Half Moon Transcatheter Mitral Valve Repair (TMVr) Study

    Principal Investigator:

    Susheel Kumar Kodali, MD
    This Early Feasibility Study (EFS) is looking at the investigative device called the Half Moon TMVrSystem to see if it is safe and effective in treating patients with severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve surgery. The system is designed so that a catheter can gain access to the heart by way of a large artery in the leg or by a small surgical passage through the walls between the right and left chamber of the heart. The implant then anchors on the leaflets of the valve in a certain manner. The Transcatheter Mitral Valve Replacement system...

  • The Leaflex Early Feasibility Study Protocol in Patients with Symptomatic Severe Aortic Stenosis

    Principal Investigator:

    Susheel Kumar Kodali, MD
    This is a prospective, multicenter, non-randomized, single-arm, open-label clinical study, sponsored by Pi-Cardia. Fifteen (15) patients with symptomatic severe Aortic Stenosis (narrowing of the aortic valve) who are considered operable but are not recommended by the heart team for immediate treatment with surgical or transcatheter aortic valve replacement will be treated with the Leaflex Performer in up to 7 clinical sites. All enrolled patients will be followed up at 30 days and at 3, 6, 9, and 12 months post-procedure.

  • The Progress Trial - Evaluating Transcatheter Aortic Valve Replacement (TAVR)

    Principal Investigator:

    Susheel Kumar Kodali, MD
    The study is to determine whether aortic valve replacement is helpful for patients who have moderate-severe, calcific, aortic stenosis (a narrowing of the aortic heart valve, where calcium has attached to the valve surface, resulting in obstructed blood flow) and do not have symptoms. Subjects will be randomly assigned, l to one of two groups: (1) Treatment Group: Doctor will use the SAPIEN 3 or SAPIEN 3 Ultra Transcatheter Heart Valve system to replace your valve. or (2) Clinical Surveillance Group: If assigned to this group, subject will not have their heart valve replaced. However, the...

Pages